ART6043
Asset
Inhibits DNA polymerase theta, impairing DNA repair and enhancing cancer cell killing in combination with PARP inhibitors.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- DNA damage response
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
3No named disease
Phase 2, artios.com, 10 Oct 2026
Breast cancer
Phase 1, globenewswire.com, 7 Oct 2026
Solid tumour
Phase 1, globenewswire.com, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.